Overview

A Phase I Study to Evaluate the Safety and PK of ND-340 in Healthy Volunteers

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study focuses on ND-340 extended release injection suspension for healthy volunteers with a one-time nerve blockade to determine the safety, tolerability, and pharmacokinetic profile.
Phase:
Phase 1
Details
Lead Sponsor:
Nang Kuang Pharmaceutical Co., Ltd.
Treatments:
Bupivacaine